Advancing early detection of type 1 diabetes through screening

Type 1 diabetes (T1D) is a lifelong autoimmune condition that often progresses silently for years before symptoms emerge. Early detection through islet autoantibody screening offers an opportunity to identify individuals at risk before clinical diagnosis, supporting proactive monitoring and intervention strategies. Today, an estimated 9–10 million people worldwide live with T1D, and incidence continues to rise across both pediatric and adult populations. Projections suggest prevalence could increase by 27–92% by 2040, creating a growing public health and economic challenge. Compounding this issue, up to 90% of new diagnoses occur in individuals without a family history, limiting the impact of traditional risk based screening approaches.

This whitepaper explores how advances in early detection, specifically islet autoantibody screening are reshaping the T1D care pathway. Identifying individuals in presymptomatic stages can occur years before clinical diagnosis, opening a critical window for monitoring, education, and proactive intervention. Early identification is strongly associated with a reduced risk of diabetic ketoacidosis (DKA) at diagnosis, a life threatening and costly emergency that remains common across the UK and EU, particularly among children. Beyond clinical outcomes, the paper examines the substantial economic burden associated with T1D. Diabetes accounts for approximately 12% of global health expenditure. In the UK, total diabetes costs are estimated at £10.7 billion annually, nearly 6% of total NHS spending, with close to 60% driven by largely preventable complications rather than routine care. Without intervention, overall costs are projected to rise to nearly £18 billion by 2035. Similar spending patterns are seen across Europe, where inpatient admissions and long term complications consume a significant share of healthcare resources.

Healthcare systems across the UK and EU are increasingly prioritizing precision medicine, population-level screening, and preventive chronic disease management. Early T1D detection can help improve patient outcomes while reducing downstream healthcare costs. This whitepaper outlines how Revvity’s type 1 diabetes screening capabilities support these goals, helping healthcare organizations move from reactive diagnosis to proactive care.

Download the whitepaper to learn how early detection and islet autoantibody screening can identify individuals at risk for Type 1 Diabetes before symptom onset and support proactive care strategies.

This testing service has not been cleared or approved by the U.S. Food and Drug Administration. Testing services may not be licensed in accordance with the laws in all countries. The availability of specific test offerings is dependent upon laboratory location. The content on this page is provided for informational purposes only, not as medical advice. It is not intended to substitute the consultation, diagnosis, and/or treatment provided by a qualified licensed physician or other medical professionals.

What you'll learn about Type 1 Diabetes autoantibody screening

• Why early detection matters in Type 1 Diabetes
  Learn how islet autoantibody screening can identify individuals at risk for Type 1 Diabetes before symptoms appear, enabling proactive monitoring and earlier intervention.
• How autoantibody testing supports risk stratification
  Understand the role of key T1D-associated autoantibodies, including IAA, GADA, IA-2A, and ZnT8A, in identifying presymptomatic disease and assessing progression risk.
• The clinical impact of earlier identification
  Explore how early detection can support informed care planning, patient preparedness and efforts to reduce the risk of diabetic ketoacidosis (DKA).
• The case for population-level T1D screening
  Discover the growing rationale for expanding screening beyond family-history-based testing to broader pediatric and at-risk populations.
• How proactive screening can support healthcare systems
  Learn how scalable screening approaches may help shift care from reactive treatment toward preventive disease management.